Gilead Sciences, Inc. revealed a collaboration with the U.S. State Department and the President’s Emergency Plan for AIDS Relief (PEPFAR) to distribute lenacapavir as an injectable HIV-1 capsid inhibitor for HIV prevention as pre-exposure prophylaxis (PrEP). The initiative, part of Gilead's broader strategic initiatives, aims to provide this treatment twice yearly. The partnership integrates the strengths and resources of PEPFAR and the Global Fund to enhance the fight against HIV.